About us

Offerings

Pricing

Prime Ratings

Articles

Prime
Funds
Prime
Deposits
Term
Insurance
Prime
ETF's
MF
Portfolios
Ready-to-use
Portfolios
Insurance
Rankings
Thematic
Investing
Insurance
Comparison

Financial insights for intelligent investors

We Research.
You Profit.

Why you need PrimeInvestor?

Our unbiased, research-backed recommendations help you invest right and stay right.

Specifically four

Play Video

Read more

Meet our team

We’re a passionate,
driven team that’s transforming an industry.

Srikanth Meenakshi

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi sodales porta odio sit amet maximus. Etiam vel arcu blandit risus pellentesque.

Vidya Bala

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi sodales porta odio sit amet maximus. Etiam vel arcu blandit risus pellentesque.

Bhavan Acharya

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi sodales porta odio sit amet maximus. Etiam vel arcu blandit risus pellentesque.

Aarati Krishnan

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi sodales porta odio sit amet maximus. Etiam vel arcu blandit risus pellentesque.

Our Financial Insights

Cut out the market noise.
Stay on top of what’s relevant to you.

glenmark life sciences, glenmark life sciences ipo, IPO review

IPO Review: Glenmark Life Sciences – Should you invest?

Glenmark Life Sciences (GLS) is a generic API (Active Pharmaceutical Ingredients) manufacturer and a subsidiary of Glenmark Pharmaceuticals. The Glenmark Life Sciences IPO is worth Rs. 1,514 crore, comprising fresh issue of Rs.1,060 crore and an offer for sale worth Rs.454 crore by Glenmark Pharmaceuticals. Should you invest in the IPO of this high-value, non-commoditized API player?

Premium article available only to subscribers.

Read more

IPO Review: Glenmark Life Sciences – Should you invest?

Glenmark Life Sciences (GLS) is a generic API (Active Pharmaceutical Ingredients) manufacturer and a subsidiary of Glenmark Pharmaceuticals. The Glenmark Life Sciences IPO is worth Rs. 1,514 crore, comprising fresh issue of Rs.1,060 crore and an offer for sale worth Rs.454 crore by Glenmark Pharmaceuticals. Should you invest in the IPO of this high-value, non-commoditized API player?

Read more

How to evaluate banking and finance stocks

There are certain characteristics which make evaluating banking and finance stocks different from others which produce goods and services. Money cannot be lent to someone unless there is an inflow by way of capital or debt. Since it is not practical to lend only from capital, borrowing (or leverage) is the sustaining food for this business. Naturally in using this leverage, there are good and bad apples.

Premium article available only to subscribers.

Read more

Why you don’t need a Rs 1 crore health policy

Recent reports suggest that as many as 35% of health insurance buyers in recent times – mainly in their 30s and 40s – are buying Rs 1 crore health insurance plans, against just 5% who used to buy them earlier.

Premium article available only to subscribers.

Read more

Read more articles

Our happy customers

What they say about us

Mandar Diwakar
Mandar Diwakar@MandarDiwakar
Read More
Wish you all the very best. You are doing a great job of educating and guiding "do it yourself" investors like me. I feel proud to be a primeinvestor subscriber.
Sriram Murthy
Sriram Murthy@sriramaussie
Read More
I subscribed and must say it's one of the best... @srikan2 and @AaratiKrishnan I have been following in various platforms like naanayam vikatan and business line... Though I had some idea of certain funds but their articles and recommended funds confirms that we r on d right path
Karthik Raghu
Karthik Raghu@KarthikRaghu10
Read More
This site is brilliant... Started with one article and ended up reading four! Crystal clear, actionable and precise! All the best to your team.
Nithin Lakshmanan
Nithin Lakshmanan@nithin_lakshman
Read More
Fantastic initiative. Wonderful pricing! Thumbs up!👌🏽
Previous
Next

PrimeInvestor in the news

Recent media coverage

Replace large-cap funds with multicaps
MF inflows to moderate in March
PrimeInvestor to guide retail investors
Replace large-cap funds with multicaps
Replace large-cap funds with multicaps
Replace large-cap funds with multicaps

Read more articles

Redwood Research

A member of FinBlue,
a FinTech center of excellence
Software Technology Parks of India
Suite #14, No. 5, SH 49A,
Tharamani, Chennai,
Tamil Nadu-600113.

About PrimeInvestor

Useful Links

Terms

Legal Disclaimer : Redwood Research (with brand name PrimeInvestor) is an independent research entity offering research services on personal finance products to customers. We are a SEBI registered Research Analyst (Registration: INH200007478). The content and reports generated by the entity does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities. All content and information is provided on an ‘As Is’ basis by PrimeInvestor. Information herein is believed to be reliable but PrimeInvestor does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. The services rendered by PrimeInvestor are on a best effort basis. PrimeInvestor does not assure or guarantee the user any minimum or fixed returns. PrimeInvestor or any of its officers, directors, partners, employees, agents, subsidiaries, affiliates or business associates will not liable for any losses, cost of damage incurred consequent upon relying on investment information, research opinions or advice or any other material/information whatsoever on the web site, reports, mails or notifications issued by PrimeInvestor or any other agency appointed/authorised by PrimeInvestor. Use of the above-said information is at the user’s own risk. The user must make his own investment decisions based on his specific investment objective and financial position and using such independent advisors as he believes necessary. All intellectual property rights emerging from this website, blog, and investment solutions are and shall remain with PrimeInvestor. All material made available is meant for the user’s personal use and such user shall not resell, copy, or redistribute the newsletter or any part of it, or use it for any commercial purpose. PrimeInvestor, or any of its officers, directors, employees, or subsidiaries have not received any compensation/ benefits whether monetary or in kind, from the AMC, company, government, bank or any other product manufacturer or third party, whose products are the subject of its research or investment information. The performance data quoted represents past performance and does not guarantee future results. Investing in financial products involves risk. Mutual Fund Investments are subject to market risk, read all scheme related documents carefully. As a condition to accessing PrimeInvestor’s content and website, you agree to our Terms and Conditions of Use, available here. This service is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Redwood Research or its affiliates to any registration or licensing requirement.

Copyright © 2020 PrimeInvestor